Schrödinger reveals breakthrough preclinical data on cancer therapies

In the United States, Schrödinger, Inc. announced the presentation of new preclinical data regarding two investigational cancer therapies at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. The meeting will take place from April 25 to 30, 2025, in Chicago, Illinois. The data includes findings on SGR-3515, a Wee1/Myt1 inhibitor, and SGR-4174, an SOS1 inhibitor. The presentation aims to shed light on the potential of these compounds, especially SGR-4174, as viable treatments for cancers driven by KRAS mutations. In addition to the drug-specific data, the presentation will feature a machine learning model developed by Schrödinger. This model forecasts responses to drug combinations that include the Wee1 inhibitor across various cancer cell lines. The utility of machine learning in optimizing therapeutic strategies is recognized as a significant advancement in the field of oncology. This will mark the first official presentation of preclinical data regarding SGR-4174, emphasizing its unique profile in preclinical oncology models. Details about the timings and locations for the presentations at the AACR meeting were outlined. For SGR-3515, a study titled 'Optimization of therapeutic index of SGR-3515, a first-in-class Wee1/Myt1 inhibitor through intermittent dosing for monotherapy and combination with chemotherapy in xenograft tumor models' will be showcased on April 28, 2025. Furthermore, the characterization of SGR-4174 will be presented under the title, 'Preclinical characterization of SGR-4174, a potent and selective SOS1 inhibitor for the treatment of pan KRAS mutant cancers in combination with KRAS pathway inhibitors' on April 29, 2025. Schrödinger's computational platform serves as the backbone for both drug development and material design, making it a leader in molecular discovery. The company's deep-rooted expertise, built over more than 30 years of investment, empowers its collaborations with biopharmaceutical entities and academic institutions. The firm is also engaged in multiple clinical-stage oncology programs targeting advanced solid tumors, with the expected outcomes from these presentations potentially paving the way for future clinical trials. Schrödinger's commitment to addressing KRAS-driven cancers is particularly noteworthy, as these mutations are prevalent in various aggressive cancer types, presenting significant challenges in treatment efficacy and patient outcomes.